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A B S T R A C T
Background
The insertion of central venous catheters (CVCs) may be associated with peri- and post-procedural bleeding. People who require a
central line often have disorders of coagulation as a result of their underlying illness, co-morbidities or the effects of treatment. Clinical
practice in some institutions is to mitigate the risk of bleeding in these patients by prophylactically transfusing fresh frozen plasma
(FFP) in order to correct clotting factor deficiencies prior to central line insertion. However, FFP transfusion is not without risk, and
it remains unclear whether this intervention is associated with reduced rates of bleeding or other clinically-meaningful outcomes.
Objectives
To assess the effect of different prophylactic plasma transfusion regimens prior to central line insertion in people with abnormal
coagulation.
Search methods
We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane
Library 2016, Issue 3), PubMed (e-publications only), Ovid MEDLINE (from 1946), Ovid Embase (from 1974), the Transfusion
Evidence Library (from 1950) and ongoing trial databases to 1 March 2016.
Selection criteria
We included RCTs involving transfusions of plasma to prevent bleeding in people of any age with abnormal coagulation requiring
insertion of a central venous catheter, published in English.
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
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Main results
We identified four trials eligible for inclusion, of which three are ongoing. We did not exclude any studies because they were not
published in English.
The included study randomised 81 adults in intensive care whose INR (International Normalised Ratio) was greater than or equal
to 1.5 to no FFP or to a single dose of 12 mL/kg FFP prior to undergoing central venous catheterisation (58 participants) or other
invasive procedure (23 participants). It is the subgroup of 58 adults undergoing CVC insertion that were included in this review, the
study authors provided unpublished data for this review’s outcomes.
The quality of the evidence was low or very low across different outcomes according to the GRADE methodology. The included study
was at high risk of bias due to lack of blinding of participants and personnel and imbalance in the number of participants who had
liver disease between study arms.
Therewas insufficient evidence to determine a difference inmajor procedure-related bleedingwithin 24 hours (oneRCT; 58 participants;
no events in either study arm, very low-quality evidence).We are very uncertain whether FFP reduces minor procedure-related bleeding
within 24 hours of the study (one RCT; 58 participants, RR 0.67, 95% CI 0.12 to 3.70, very low-quality evidence).
No studies were found that looked at: all-cause mortality; the proportion of participants receiving plasma or red cell transfusions;
serious adverse reactions (transfusion or line-related complications); number of days in hospital; change in INR; or quality of life.
The three ongoing studies are still recruiting participants (expected recruitment: up to 355 participants in total). and are due to be
completed by February 2018.
Authors’ conclusions
There is only very limited evidence from one RCT to inform the decision whether or not to administer prophylactic plasma prior to
central venous catheterisation for people with abnormal coagulation. It is not possible from the current RCT evidence to recommend
whether or not prophylactic plasma transfusion is beneficial or harmful in this situation. The three ongoing RCTs will not be able to
answer this review’s questions, because they are small studies and do not address all of the comparisons included in this review (355
participants in total). To detect an increase in the proportion of participants who had major bleeding from 1 in 100 to 2 in 100 would
require a study containing at least 4634 participants (80% power, 5% significance).
P L A I N L A N G U A G E S U M M A R Y
Plasma transfusions prior to insertion of central lines for people with abnormal coagulation
Review question
We evaluated the evidence about whether people with abnormal coagulation (poor blood clotting) require a plasma transfusion prior
to insertion of a central line (central venous catheter (CVC)), and if so, what is the degree of abnormal coagulation at which a plasma
transfusion is required.
Background
People with abnormal coagulation often require the insertion of central lines. Central lines are catheters whose tip usually lies in
one of two main veins returning blood to the heart. They have a number of uses including: intensive monitoring and treatment of
critically-ill patients; giving nutrition into a vein (when the patient cannot eat); giving chemotherapy or other irritant drugs with fewer
complications; and when patients require long-term repeated treatments in to a vein. Current practice in many countries is to give
plasma transfusions to prevent serious bleeding due to the procedure if blood tests to assess clotting are abnormal. The risk of bleeding
after a central line insertion appears to be low if the clinician uses ultrasound to guide insertion of the line. Correction of clotting
abnormalities with fresh frozen plasma (FFP) is not without risks of its own, and it is unclear whether this practice is beneficial or
harmful. People may be exposed to the risks of a plasma transfusion without any obvious clinical benefit.
Study characteristics
The evidence is current to March 2016. In this review we identified four randomised controlled trials, three trials are still recruiting
participants and are due to complete recruitment by February 2018. The completed trial (58 participants) compared plasma transfusion
to no plasma transfusion prior to central line insertion.
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Key results
There was not enough evidence to determine whether plasma transfusions affected minor or major procedure-related bleeding. The
included study did not report the number of people dying due to any cause, the number of people receiving red cell or plasma
transfusions, the occurrence of transfusion or line-related complications, length of time in hospital, correction of clotting abnormalities,
or quality of life.
Quality of the evidence
The quality of the evidence is very low because this review includes only one small study.
Authors’ conclusions
The ongoing studies (expected to recruit 355 participants in total) will be unable to provide sufficient data for this review’s primary
outcomes because major bleeding and mortality are uncommon. We would need to design a study with at least 4634 participants to
be able to detect an increase in the number of people who had major bleeding from 1 in 100 to 2 in 100. It is not possible from the
current randomised controlled trial evidence to recommend whether or not prophylactic plasma transfusion is beneficial or harmful in
this situation.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Comparison of plasma transfusions versus no plasma transfusions
Patient or population: people with abnormal coagulat ion requiring a central venous catheter
Setting: In hospital
Intervention: prophylact ic plasma transfusion
Comparison: no plasma transfusions
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no plasma
transfusions
Risk with prophylactic
plasma transfusion
M ajor procedure- re-
lated bleeding
follow-up: 24 hours
There were no major procedure-related bleeds in
either of the study arms
Not
est imable
58
(1 RCT)
⊕©©©
VERY LOW 12
All- cause mortality
follow-up: 30 days
- - - - Not
reported
Respiratory de-
terioration attributable
to transfusion-associ-
ated circulatory over-
load (TACO), transfu-
sion- related acute lung
injury (TRALI) or trans-
fusion-associated dys-
pnoea (TAD)
- - - - - Not
reported
M inor procedure- re-
lated bleeding
follow-up: 24 hours
Study populat ion RR 0.67
(0.12 to 3.70)
58
(1 RCT)
⊕©©©
VERY LOW 23
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103 per 1000 69 per 1000
(12 to 383)
Proportion of partici-
pants receiving plasma
transfusions
- - - - - Not
reported
Line- related complica-
tions
- - - - - Not
reported
Quality of life - - - - - Not
reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by 2 for very serious imprecision. The included study was a small study and this is a rare outcome with no events in either study
arm
2 Downgraded by 1 for serious risk of bias. There was a high risk of performance bias and other bias
3 Downgraded by 2 for very serious imprecision. The included study was a small study and the 95% confidence interval of the risk ratio includes
the possibility of significant harm or significant benefit.
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B A C K G R O U N D
Description of the condition
Coagulopathy refers to the condition in which the blood’s ability
to clot is impaired (Hunt 2014). People requiring a central line
(central venous catheter (CVC)) often become coagulopathic as a
consequence of their underlying illness, co-morbidities or the ef-
fects of treatment. Central venous catheters are catheters with tips
that lie within the proximal third of the superior vena cava, the
right atrium or the inferior vena cava (Bishop 2007; Smith 2013).
They can be inserted through a superficial vein (e.g. the basilic or
cephalic veins in the arm) or a central vein (most commonly the
internal jugular, subclavian or femoral veins) (Bishop 2007; Smith
2013). There are four main types: 1) a non-tunnelled line into a
central vein (short-term use); 2) a line inserted into a superficial
vein (medium-term use); 3) a tunnelled line (long-term use); 4)
a totally implanted device (long-term use) (Bishop 2007; Smith
2013). They have a number of uses, these include: administration
of chemotherapy and other irritant drugs with fewer complica-
tions; intensive monitoring and treatment of critically ill patients;
administration of total parenteral nutrition; and long-term inter-
mittent intravenous access for patients requiring repeated treat-
ments (Smith 2013). People requiring CVCs can have a variety
of conditions and include people with liver failure, people who
are critically ill and people requiring chemotherapy (Bishop 2007;
Smith 2013).
A large national study of fresh frozen plasma (FFP) use in criti-
cal illness reported that 30% of people admitted to the intensive
care unit (ICU) developed an abnormality of coagulation (Walsh
2010). The aetiology of coagulopathy in critical illness is com-
plex and multi-factorial; sepsis, haemodilution, haemorrhage, dis-
seminated intra-vascular coagulation, hepatic and renal disease
and anti-coagulant medication are all implicated (Hunt 2014).
The causes of coagulopathy in non-critically ill people undergo-
ing CVC insertion are similarly broad. FFP is widely used in the
management of coagulopathic patients with abnormal laboratory
tests of blood coagulation (prolonged prothrombin time (PT) or
elevated international normalised ratio (INR)), and may be ad-
ministered as part of the resuscitation of actively bleeding patients,
or as prophylaxis to prevent bleeding in coagulopathic patients
undergoing invasive procedures such as CVC insertion.
Description of the intervention
Current practice in many centres is to correct disordered coagula-
tion with FFP transfusion prior to internal jugular, femoral or sub-
clavian venous catheterisation, in order to mitigate the risk of se-
rious peri- or post-procedural bleeding. Plasma is the non-cellular
component of blood and is prepared either from the centrifugation
of whole blood or by plasmapheresis (Benjamin 2012). FFP refers
to plasma that is frozenwithin eight hours to -30°C,whereas frozen
plasma (F24) is that which is frozen within 24 hours. Both contain
concentrations of clotting factors equivalent to those found in in
vivo blood, although the levels of factor V and VIII fall rapidly on
thawing (Stanworth 2007). Current recommendations regarding
the correction of coagulopathy prior to CVC insertion reflect ex-
pert opinion rather than high-quality evidence from randomised
controlled trials. An INR greater than or equal to 1.5 is frequently
advocated as the threshold above which patients should undergo
correction of coagulopathy prior to CVC insertion (Bishop 2007;
Hunt 2014). Whilst the use of standard laboratory tests of co-
agulation to assess bleeding has been criticised, an INR over 1.5
demarcates the level above which the activity of some coagulation
factors falls to less than 50% (Juffermans 2014). An alternative
approach to transfusing based on an INR threshold (which only
detects low coagulation factor levels) is to use a test such as ro-
tational thromboelastometry (ROTEM) or thromboelastography
(TEG) that assesses how well a blood clot forms in whole blood
(haemostasis). ROTEM and TEG not only assess coagulation fac-
tor function, but also platelet function, strength of the clot and
whether the clot is rapidly broken down.
Recent studies report that 15% to 26% of non-bleeding critically
ill patients receive prophylactic FFP transfusions prior to an in-
vasive procedure such as CVC insertion (Dara 2005; Stanworth
2010; Stanworth 2011). However, there remains substantial het-
erogeneity in clinicians’ views about the effectiveness of this inter-
vention, with doubts over its effectiveness and the balance of the
risk-benefit ratio (Watson 2011).
How the intervention might work
Plasma transfusion is administered to coagulopathic patients in
order to correct multiple clotting factor deficiencies and therefore
reduce the incidence of bleeding. However, although a dose of
10 mL to 15 mL/kg is required to significantly improve the INR
(O’Shaughnessy 2004), patients are commonly under-dosed and
therefore exposed to the risks associated with FFP transfusion, but
not the proposed benefits (Hall 2012). It remains unclear whether
FFP transfusion in coagulopathic non-bleeding patients, despite
improving standard laboratory tests of coagulation, reduces the in-
cidence of clinically important bleeding or improves other mean-
ingful patient-oriented outcomes such as mortality. Clinical stud-
ies also indicate that the INR is oftenminimally reduced following
FFP administration, especially when only modestly increased pre-
transfusion (Stanworth 2011).
Risks associated with the intervention
The risks associated with FFP transfusion include transfusion-
associated lung injury (Khan 2007; Rana 2006), transfusion-as-
sociated circulatory overload (Narick 2011), multi-organ failure
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(Watson 2009), and sepsis (Sarani 2008). The requirement to ad-
minister FFP to correct coagulopathy prior to central line inser-
tion may additionally delay the start of treatments such as vasoac-
tive medication, which may be time-critical in an emergency sit-
uation. Delays in initiating treatment may lead to poorer patient
outcomes (increased morbidity and mortality).
Why it is important to do this review
The evidence to support the use of prophylactic FFP transfusion
in coagulopathic patients requiring CVC insertion is weak (Hunt
2014; Stanworth 2007; Tinmouth 2011). There is no high-qual-
ity evidence, outside the setting of major trauma and haemor-
rhagic shock, that FFP administration improves mortality (Murad
2010). Standard laboratory tests of coagulation poorly reflect in
vivo haemostasis (Holland 2006), and abnormalities in INR and
PT may not increase the risk of bleeding during CVC insertion
(Segal 2005). Several case series have demonstrated the safety
of performing invasive procedures without clinically significant
bleeding in patients with an elevated INR who did not receive
FFP cover (Doerfler 1996; Fisher 1999; Foster 1992; Haas 2010;
Mumtaz 2000; Weigand 2009). The use of an INR threshold
above which FFP transfusion is required prior to CVC insertion
has therefore been called into question. It is uncertain whether
plasma transfusions are effective at preventing bleeding in patients
with deranged coagulation undergoing an invasive procedure. If
effective, the INR threshold above which plasma transfusions are
clinically effective is also uncertain. Wide variation in the use of
FFP prior to central venous catheterisation exists, indicating sig-
nificant clinician uncertainty and potentially exposing patients to
varying risk (Watson 2011).
O B J E C T I V E S
To assess the effect of different prophylactic plasma transfusion
regimens prior to central line insertion in people with abnormal
coagulation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs), irrespec-
tive of publication status published in English.
Types of participants
We included study participants of any age with abnormal coag-
ulation (as defined by the studies) requiring insertion of a cen-
tral venous catheter (CVC) (tunnelled or untunnelled), or porta-
cath. We excluded participants who were experiencing clinically
significant bleeding at the time of the catheter insertion because
such participants are routinely resuscitated with blood products
including plasma.
Types of interventions
We included RCTs comparing two types of plasma transfusion
policy.
• No plasma transfusion prior to central line insertion versus:
◦ plasma transfusion prior to central line insertion when
the INR is 1.5 to 3 times control; OR
◦ plasma transfusion when the INR is greater than 3
times control; OR
◦ plasma transfusion when rotational
thromboelastography (TEG) is above a certain threshold (as
defined by the study).
• Plasma transfusion prior to central line insertion when the
INR is greater than 1.5 times control versus:
◦ plasma transfusion prior to central line insertion when
the INR is 2 to 3 times control; OR
◦ plasma transfusion when the INR is greater than 3
times control; OR
◦ plasma transfusion when rotational TEG is above a
certain threshold (as defined by the study).
We planned to report each analysis separately, as subgroups within
the two main comparisons.
Types of outcome measures
Primary outcomes
• Major procedure-related bleeding within 24 hours of the
procedure.
Defining procedure-related bleeds can be challenging as coagulo-
pathic participants may bleed spontaneously in the absence of an
intervention. We have sought to capture this group as accurately as
possible by excluding participants who are already actively bleed-
ing at the time of CVC insertion, and by defining ’procedure-
related bleeding’ as that causing a significant fall in haemoglobin
(Hb), e.g. 20 g/L or greater in the absence of another cause; a fall
in systolic blood pressure (SBP) of at least 20mmHg or an increase
in heart rate (HR) of at least 20 beats perminute (BPM) or greater;
haemothorax (blood in the space between the outside of the lungs
and the inside of the chest wall); requiring an intervention such
as a transfusion to treat bleeding; or major bleeding (not further
defined) as reported by individual studies.
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• All-cause mortality up to 30 days after the procedure.
Secondary outcomes
• Minor procedure-related bleeding within 24 hours of the
procedure (defined as prolonged bleeding at the insertion site,
which only requires treatment with a pressure bandage, or
haematoma at the insertion site), or minor bleeding (not further
defined) as reported by individual studies.
• Serious adverse events:
• ◦ Transfusion-related complications within 24 hours of
the procedure (including transfusion-related acute lung injury
(TRALI), transfusion-transmitted infection, transfusion-
associated circulatory overload (TACO), transfusion-associated
dyspnoea (TAD), acute transfusion reactions);
◦ Line-related complications within seven days of the
procedure (infection, thrombosis, other).
• Total number of days in hospital.
• Proportion of participants receiving plasma transfusions
and red cell transfusions within 24 hours of the procedure.
• Change in INR up to 24 hours following the procedure.
• Quality of life, as defined by the individual studies.
Search methods for identification of studies
The Systematic Review Initiative’s Information Specialist (CD)
formulated the search strategies in collaboration with the
Cochrane Haematological Malignancies Group.
Electronic searches
We limited our searches to five main electronic databases and two
ongoing trial databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL, 2016, issue 3, (1 March 2016)) (Appendix 1);
• PubMed (e-publications only up to 1 March 2016)
(Appendix 2);
• MEDLINE (1946 to 1 March 2016) (Appendix 3);
• Embase (1974 to 1 March 2016) (Appendix 4);
• Transfusion Evidence Library (
www.transfusionevidencelibrary.com) (1950 to 1 March 2016)
(Appendix 5)
We searched for ongoing RCTs to 1 March 2016 in the following
databases:
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (Appendix 6);
• ClinicalTrials.gov (Appendix 7).
We combined searches in MEDLINE with the Cochrane RCT
highly sensitive search filter, as detailed in Chapter six of
the Cochrane Handbook for Systematic Reviews of Interventions
(Lefebvre 2011). We combined searches in Embase with the rel-
evant SIGN (Scottish Intercollegiate Guidelines Network) RCT
studies filter (www.sign.ac.uk/methodology/filters.html). We ex-
cluded studies published in languages other than English. We did
not limit searches by year of publication or publication type.
Searching other resources
We handsearched the reference lists of included studies in order
to identify further relevant studies, and made contact where ap-
propriate with lead authors of included studies to identify any un-
published material, missing data or information regarding ongo-
ing studies.
Data collection and analysis
Selection of studies
We selected studies for inclusion with reference to Chapter seven
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a). The Systematic Review Initiative’s Informa-
tion Specialist (CD) initially screened all search hits for relevance
against the eligibility criteria and discarded all those that were
clearly irrelevant. Thereafter, two review authors (DH, LE) in-
dependently screened all the remaining references for relevance
against the full eligibility criteria using DistillerSR. We retrieved
full-text articles for all references for which a decision on eligibility
could not be made from the title and abstract alone. We requested
additional information from study authors as necessary to assess
the eligibility for inclusion of individual studies. The two review
authors discussed the results of study selection in order to resolve
any discrepancies between themselves. In the event that this was
not possible, we referred the decision on eligibility to a third review
author (TW). We reported the results of study selection using a
PRISMA flow diagram (Moher 2009) (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
As recommended in theCochrane Handbook for Systematic Reviews
of Interventions, two review authors (DH, LE) independently ex-
tracted data onto standardised forms and performed a cross-check
using DistillerSR software (Higgins 2011a). The two review au-
thors reached a consensus without the need for a third review au-
thor (TW). The review authors were not blinded to names of au-
thors, institutions, journals or the study outcomes. We planned to
extract the following information for each study.
• Source: study ID; report ID; review author ID; date of
extraction; ID of author checking extracted data; citation of
paper; contact authors details.
• General study information: publication type; study
objectives; funding source; conflict of interest declared; other
relevant study publication reviewed.
• Study details and methods: location; country; setting;
number of centres; total study duration; recruitment dates;
length of follow-up; power calculation; primary analysis (and
definition); stopping rules; method of sequence generation;
allocation concealment; blinding (of clinicians, participants and
outcome assessors); and any concerns regarding bias.
• Characteristics of interventions: number of study arms;
description of experimental arm; description of control arm; type
of plasma product (e.g. fresh frozen plasma (FFP), frozen plasma
(F24) (including solvent detergent and methylene blue treated
plasma); type of thromboplastin used to measure INR.
• Characteristics of participants: age; gender; primary
diagnosis; type of catheter inserted; platelet count.
• Participant flow: total number screened for inclusion; total
number recruited; total number excluded; total number
allocated to each study arm; total number analysed (for review
outcomes); number of allocated participants who received
planned treatment; number of dropouts with reasons (percentage
in each arm); protocol violations; missing data.
• Outcomes: major procedure-related bleeding within 24
hours of the procedure; minor procedure-related bleeding within
24 hours of the procedure; transfusion-related complications
within 24 hours of the procedure; line-related complications
within seven days of the procedure; total number of days in
hospital; proportion of participants receiving plasma transfusions
within 24 hours; change in INR up to 24 hours post-procedure;
all-cause mortality up to 30 days from the procedure; quality of
life.
Assessment of risk of bias in included studies
We assessed the included RCT using the Cochrane ’Risk of bias’
tool as described in Chapter eight of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011b). Two re-
view authors (DH, LE) worked independently to assess each ele-
ment of potential bias listed below as ’high’, ’low’ or ’unclear’ risk
of bias. We reported a brief description of the judgement state-
ments upon which the authors have assessed potential bias in the
Characteristics of included studies table. We reach a consensus on
the degree of risk of bias through comparison of the review au-
thors statements without the need for a third review author (TW).
We used Cochrane’s tool for assessing risk of bias, including the
following domains.
• Selection bias: random sequence generation and allocation
concealment.
• Performance bias: blinding of participants and personnel.
• Detection bias: blinding of outcome assessment.
• Attrition bias: incomplete outcome data.
• Reporting bias: selective reporting.
• Other bias.
Measures of treatment effect
For continuous outcomes, we planned to record the mean, stan-
dard deviation and total number of participants in both the treat-
ment and control groups, however no continuous outcomes were
reported in the included study. In future updates of this review,
we will perform analyses for continuous outcomes that use the
same scale, using the mean difference (MD) with 95% confidence
intervals (CIs). For continuous outcomes measured with different
scales, we will present the standardised mean difference (SMD).
We planned to extract and report hazard ratios (HR), if available
for mortality data, however there were no deaths in the included
study. In future updates of this review, we will extract and report
HRs, if available for mortality data. If HRs are not available, we
will make every effort to estimate as accurately as possible the HR
using the available data and a purpose-built method based on the
Parmar and Tierney tool (Parmar 1998; Tierney 2007).
For dichotomous outcomes we recorded the number of events
and the total number of participants in both the treatment and
control groups. We did not report the pooled risk ratio (RR) with
a 95% CI because there was only one included trial. Where the
number of observed events was small (less than 5% of sample
per group), and where trials have balanced treatment groups, we
planned to report the Peto odds ratio (OR) with 95% CIs (Deeks
2011). However in the only analysis performed (minor bleeding),
the observed event rate was more than 5%, therefore a Peto odds
ratio was not performed.
Where the data allowed, we undertook quantitative assessments
using Review Manager 5.
Where appropriate, we planned to report the number needed to
treat for an additional beneficial outcome (NNTB) and the num-
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ber needed to treat or an additional harmful outcome (NNTH)
with CIs, however the only analysis performed did not demon-
strate a benefit or harm.
If we could not report the available data in any of the formats
described above, we performed a narrative report and, where ap-
propriate, we planned to present the data in tables.
Unit of analysis issues
There were no unit of analysis issues within the included study.
In future updates of this review, we will treat any unit of analysis
issues in accordance with the advice given in Chapter 16 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011c). If participants are randomised more than once, we will
contact the authors of the study to provide us with data on the
CVCs associated with the initial randomisation.
Dealing with missing data
Where data were identified as missing or unclear in the published
literature, we contacted the study authors directly. In the one in-
cluded trial participants were undergoing other invasive proce-
dures besides central venous catheterisation (Müller 2015), the au-
thor provided additional unpublished data for the central venous
catheter subgroup from the general trial dataset.
Assessment of heterogeneity
We did not perform an assessment of heterogeneity as the review
included only one completed study. We had specified in the pro-
tocol that we planned to combine data to perform a meta-analy-
sis if the clinical and methodological characteristics of individual
studies were sufficiently homogeneous. We had intended to assess
statistical heterogeneity of treatment effects between studies using
a Chi2 test with a significance level at P value < 0.1. We planned
to use the I2 statistic to quantify the degree of potential hetero-
geneity and classify it as moderate if the I2 value is over 50% or
considerable if the I2 is over 80%. We had intended to explore po-
tential sources of statistical heterogeneity in each included study
and perform sensitivity analyses as appropriate.
We had anticipated that at least moderate clinical and method-
ological heterogeneity would be identified within the studies se-
lected for inclusion and intended to use the random-effects model.
If statistical heterogeneity had been considerable, we did not in-
tend to pool the studies in a meta-analysis. We planned to assess
potential causes of heterogeneity by sensitivity and subgroup anal-
yses (Deeks 2011).
Assessment of reporting biases
We did not perform a formal assessment of potential publication
bias as the review included only one trial.
In future updates of this review, where at least 10 studies are iden-
tified for inclusion in a meta-analysis, we will explore potential
publication bias (small-trial bias)
by generating a funnel plot and using a linear regression test. We
will consider a P value of less than 0.1 as significant for this test
(Lau 2006; Sterne 2011).
Data synthesis
We planned to perform analyses according to the recommenda-
tions of the Cochrane Handbook for Systematic Reviews of Interven-
tions using aggregated data for analysis (Deeks 2011). For statis-
tical analysis, we entered data into the Cochrane statistical pack-
age Review Manager 5. One review author (DH) entered the data
into the software and a second review author (LE) checked this
for accuracy.
Meta-analysis was not feasible as the review included only one
completed study.
In future updates of this review where meta-analysis is feasible, we
will use the random-effects model for pooling the data.We will use
the Mantel-Haenszel method for dichotomous outcomes or Peto
method as necessary, and we will use the inverse variance method
(and SMDs as necessary) for continuous outcomes. We will use
the generic inverse variance method for time-to-event outcomes.
If heterogeneity is found to be above 80%, we will not perform a
meta-analysis.We will comment narratively on results and we will
comment on any trends in the data within the results section of
the review.
Summary of findings
We planned to use GRADE to build separate ’Summary of find-
ings’ tables for both types of FFP transfusion regimen specified in
the Types of interventions, as suggested in Chapters 11 and 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2011a; Schünemann 2011b). The included study
compared no plasma transfusion prior to central line insertion
versus plasma transfusion prior to central line insertion when the
INR is 1.5 to 3 times control. The outcomes we included are listed
below.
• Major procedure-related bleeding within 24 hours of the
procedure.
• All-cause mortality up to 30 days after the procedure.
• Respiratory deterioration attributable to transfusion-
associated circulatory overload (TACO), transfusion-related
acute lung injury (TRALI) or transfusion-associated dyspnoea
(TAD) within 24 hours of the procedure.
• Minor procedure-related bleeding within 24 hours of the
procedure.
• Proportion of participants receiving plasma transfusions
within 24 hours of the procedure.
• Line-related complications within seven days of the
procedure (infection, thrombosis, other).
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• Quality of life.
Subgroup analysis and investigation of heterogeneity
We were unable to perform any subgroup analyses because of
insufficient data. In future updates of this review we plan to carry
out subgroup analyses for each of the following outcomes in order
to assess the effect on heterogeneity.
• Type of central line inserted (venous tunnelled, venous
untunnelled, porta-cath, whether an emergency or elective
procedure).
• Type of participants (intensive care, liver disease, other).
• Age of participants (neonate, child (one to 15 years), adult
(16 years or older)).
• Whether participants had associated platelet count
abnormalities.
In future updates of this review investigation of heterogeneity be-
tween studies will also include the following, if appropriate.
• Type of plasma component (fresh frozen plasma (FFP),
frozen plasma (F24) (including solvent detergent and methylene
blue treated plasma).
• Type of thromboplastin used to measure INR.
Sensitivity analysis
Only one completed study was identified in this review and there-
fore we performed no sensitivity analyses. In future updates of this
review if sufficient data are available we plan to assess the robust-
ness of our findings by performing the following sensitivity anal-
yses where appropriate.
• Including only those studies with a ’low’ risk of bias for
detection and selection bias.
• Including only those studies with less than a 20% dropout
rate.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies
Results of the search
The search (conducted on 1 March 2016) identified 2771 po-
tentially relevant records (see the PRISMA Flow Diagram, Figure
1). There were 2009 records after we removed duplicates. Two
review authors (LE and DH) excluded 1976 records on the basis
of the abstract. We retrieved 33 full-text articles for assessment by
the same two review authors. Four studies met the inclusion cri-
teria for review (Müller 2015; NCT02311985; NCT02561026;
NCT02637427), but three of these are ongoing (NCT02311985;
NCT02561026; NCT02637427).
Included studies
See Characteristics of included studies for full details of the in-
cluded study.
The one completed study (Müller 2015) included within this re-
view compared no plasma transfusion prior to central line inser-
tion versus plasma transfusion prior to central line insertion when
the INR was 1.5 to 3 times control.
No studies were identified that compared: no plasma transfusion
prior to central line insertion versus plasma transfusion when the
INR was greater than 3 times control; OR plasma transfusion
when rotational thromboelastography (TEG) was above a certain
threshold (as defined by the study).
No studieswere identified that compared: plasma transfusionprior
to central line insertion when the INR was greater than 1.5 times
control; versus plasma transfusion prior to central line insertion
when the INR was 2 to 3 times control; OR plasma transfusion
when the INRwas greater than 3 times control; plasma transfusion
when rotational TEG was above a certain threshold (as defined by
the study).
Study Design
The TOPIC Trial (Müller 2015) was a parallel-group, multi-cen-
tre, randomised, open-label trial with blinded endpoint evalua-
tion. Participants were enrolled from May 2010 to June 2013.
Setting
The study was conducted in the Netherlands with participants
recruited at two university hospitals and two large teaching hos-
pitals.
Participants
The study investigators planned to recruit 200 participants per
treatment arm, but owing to slow recruitment, the trial was
stopped before this target enrolment was reached. Inclusion cri-
teria included people over 18 years old admitted to the Intensive
Care Unit (ICU) with an INR of 1.5 to 3.0 and undergoing in-
sertion of a central venous catheter, thoracocentesis, percutaneous
tracheotomy, or drainage of abscess or fluid collection. The in-
vestigators provided supplementary unpublished data relating to
only those patients who underwent CVC insertion.
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Intervention and Comparator
The study compared no fresh frozen plasma (FFP) versus a single
dose of FFP (12 mL/kg) prior to an invasive procedure. Eighty-
one participants were randomised (41 no FFP, 40 FFP), of which
58 received CVC insertion and were included in this review (29
no FFP, 29 FFP).
Co-Interventions
There were no co-interventions in this study.
Outcomes
The primary outcome was procedure-related bleeding occurring
within a 24-hour period after the procedure. Secondary outcomes
included the effects of FFP on correction of INR and additional
transfusion requirements, development of lung injury within 24
hours after the intervention, the incidence of ventilator-associated
pneumonia, major bleeding and minor bleeding. Quality of life
outcomes were not reported
Funding Sources
The study was funded by ZonMw Netherlands, Organization for
Health, Research and Development, the Hague, the Netherlands
(Project 171002206).
Ongoing studies
There are three ongoing clinical trials (NCT02311985;
NCT02561026; NCT02637427). Please see Characteristics of
ongoing studies for further details.
Two ongoing studies are comparing no plasma transfusion prior to
central line insertion versus plasma transfusion prior to central line
insertion when the INR is 1.5 to 3 times control (NCT02561026;
NCT02637427). The third ongoing study is a three-arm study
comparing plasma transfusion prior to central line insertion when
the INR is greater than 1.5 times control versus plasma transfu-
sion when the INR is greater than 5 times control versus plasma
transfusion when rotational TEG is above a certain threshold
(NCT02311985).
NCT02311985
The POCKET Trial (Point-of-care versus standard coagulation tests
versus restrictive strategy to guide transfusion in chronic liver failure
patients requiring central venous line, (NCT02311985) is a sin-
gle-centre, double-blind, randomised-controlled trial that is cur-
rently enrolling participants and aims to complete recruitment by
December 2016 (personal communication with Dr Rocha). The
study is being conducted in Brazil and plans to enrol 165 partici-
pants with chronic liver disease, randomised to receive transfusion
of fresh-frozen plasma, platelets and/or cryoprecipitate guided by
the use of standard tests of coagulation (INR > 1.5, activated par-
tial thromboplastin time (APPT) > 50 seconds) versus thromboe-
lastometry (ROTEM) versus standard tests of coagulation with a
restrictive threshold (INR > 5, platelets < 25 x 109/L) prior to
central venous catheterisation.
NCT02561026
The TOPPIT Trial (Transfusion of Plasma Prior to Invasive Proce-
dures Pilot Trial, NCT02561026) is a three-centre, randomised,
parallel-assignment, open-label trial that began to enrol partici-
pants in January 2016. It plans to enrol 80 people in intensive care
over the age of 18 with an INR 1.5 to 2.5 who are undergoing an
invasive procedure (central venous catheterisation, thoracocente-
sis, bronchoscopy, endoscopy, biopsy or fluid drainage). Partici-
pants will be randomised to receive either transfusion of FFP or
no transfusion prior to the procedure.
NCT02637427
Does Plasma Reduce Bleeding in Patients Undergoing Invasive Proce-
dures (NCT02637427) is a multi-centre, single-blinded, parallel-
assignment randomised controlled trial that aims to recruit 110
participants with an INR 1.5 to 2.5 undergoing an invasive pro-
cedure at the bedside, in an endoscopy suite or in a radiology de-
partment between January 2016 and May 2017. Participants will
be randomised to receive either 10 to 20 mL/kg FFP versus no
FFP prior to the invasive procedure.
Excluded studies
See Characteristics of excluded studies for full details of excluded
studies. A total of 23 full-text articles were excluded, of which:
• nine were trials with non-eligible comparison groups
(Alport 2012; Bartelmaos 2013; Corash 2006; Etemadrezaie
2007; Freeman 1998; Holcomb 2015; Mintz 2006; Tinmouth
2008; Williamson 1999)
• five were non-randomised trials (Amarapurkar 2014;
Carino 2009; Friedman 1989; Napolitano 2012; Weigand 2009)
• three were trials which were withdrawn prior to enrolment
(NCT00233246; NCT00953901; NCT01754545)
• one trial included fewer than 10% of participants receiving
central venous catheterisation (De Pietri 2016)
• one article was a case series (Gallieni 1995)
• one article was a commentary (Harter 2004)
• three articles were secondary citations of excluded studies
Risk of bias in included studies
See Figure 2 for a visual representation of the risk of bias in the in-
cluded study. See the ’Risk of bias’ table within the Characteristics
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of included studies for further information regarding the risk of
bias identified within this trial.
Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
We assessed the risk of bias due to selection bias (sequence genera-
tion and allocation concealment) as low. The randomisation pro-
cedure was web-based and password-protected, using permuted
blocks and stratified by study centre and invasive procedure.
Blinding
Performance bias
We assessed the risk of bias due to performance bias as high. Man-
ufacture of a completely matched placebo was not considered pos-
sible and so investigators and clinicians were unblinded to the in-
tervention. Due to this lack of blinding the compared groups may
have received different amounts of attention, ancillary treatment,
and diagnostic investigations by clinicians. It is unclear howmany
participants were sedated and therefore not aware of the interven-
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tion.
Detection bias
We assessed the risk of bias due to detection bias as low. Assessment
of potential bleedingwas by a physician blinded to the intervention
who assigned a score of major, minor or no bleeding at one and
24 hours after the intervention.
Incomplete outcome data
We assessed the risk of bias due to attrition bias as low. All partici-
pants who were randomised and underwent an invasive procedure
were included in the analysis
Selective reporting
We assessed the risk of bias due to reporting bias as unclear.
The primary outcome was pre-specified and reported (“proce-
dure related relevant bleeding, occurring within 24 hours after the
procedure”) . However, changes were made to secondary out-
comes between trial registration and reporting. Acute lung injury
was reported at 24 hours, rather than 48 hours as specified in the
trial registration. No evaluation of costs was reported, despite this
being registered as a secondary outcome.
Other potential sources of bias
We assessed the risk of bias due to other bias as high. The major
limitation of this trial was that it was stopped early due to slow in-
clusion. Despite the addition of extra recruitment sites, the study
was only able to randomise 20% of the targeted participant num-
ber. There was also an imbalance in the number of participants
with a history of liver disease between treatment arms. 45% (17/
38) of participants had liver disease in the no FFP arm whereas
only 16% (6/38) had liver disease in the FFP arm. People with liver
disease are known to have re-balanced haemostasis with a decrease
in both pro-coagulant and anticoagulant clotting factors (Habib
2014; Kujovich 2015), therefore people with liver disease may be
less likely to bleed than other people with abnormal coagulation
(measured using INR).
Effects of interventions
See:Summaryoffindings for themain comparisonComparison
of plasma transfusions versus no plasma transfusions when the
INR is 1.5 prior to central venous catheter insertion
Primary outcomes
Major procedure-related bleeding within 24 hours of the
procedure
There were no episodes of major procedure-related bleeding re-
ported in either of the two arms of theMüller 2015 study (58 par-
ticipants, unpublished data provided by the study authors). There
was therefore insufficient evidence to determine a difference inma-
jor procedure-related bleeding between participants who received
no FFP prior to CVC insertion compared to those transfused FFP
(very low-quality of evidence).
All-cause mortality up to 30 days after the procedure
This was not reported for the 58 participants who underwent a
CVC insertion.
For the 76 participants in the study who underwent any proce-
dure there were 19 deaths in the FFP arm (38 participants) and
27 deaths in the no FFP arm (38 participants) (Müller 2015). Ad-
ditional linear regression performed by the study authors demon-
strated that liver disease was the sole predictor for mortality (P =
0.056).
Secondary outcomes
Minor procedure-related bleeding within 24 hours of the
procedure
This was defined as prolonged bleeding at the insertion site, which
only required treatment with a pressure bandage/haematoma at
the insertion site, or minor bleeding as reported by individual
studies. In the only included study (58 participants, unpublished
data provided by the study authors), there were two episodes of
minor procedure-related bleeding within 24 hours of central ve-
nous catheterisation in the FFP arm, compared to three episodes
in the no FFP arm (risk ratio (RR) 0.67; 95% confidence interval
(CI) 0.12 to 3.70, very low-quality of evidence) (Analysis 1.1).
Serious adverse events
Transfusion-related complications within 24 hours of the
procedure
These complications included: transfusion-related acute lung in-
jury (TRALI); transfusion-transmitted infection; transfusion-as-
sociated circulatory overload (TACO); transfusion-associated dys-
pnoea (TAD); and acute transfusion reactions.
These outcomes were not reported by the included study.
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Line-related complications within seven days of the
procedure (infection, thrombosis, other)
These outcomes were not reported by the included study.
Total number of days in hospital
This outcome was not reported by the included study.
Proportion of participants receiving plasma transfusions and
red cell transfusions within 24 hours of the procedure
This outcome was not reported by the included study.
Change in INR up to 24 hours following the procedure
This outcomewas not reported for the subgroup of 58 participants
who underwent a CVC insertion in the included study.
For the 76 participants who underwent any procedure, 38 were
randomised to receive an FFP transfusion. An FFP transfusion
resulted in a median reduction of INR from 1.8 (interquartile
range (IQR) 1.5 to 2.5) to 1.4 (IQR, 1.3 to 1.63; P < 0.001) (study
author’s own results). Only 54% of participants had an INR less
than 1.5 after an FFP transfusion (Müller 2015).
Quality of life
The included study did not report any quality of life outcome
measures.
D I S C U S S I O N
Summary of main results
Four randomised controlled trials (RCTs) met the inclusion cri-
teria, of which three are currently ongoing (NCT02311985,
NCT02637427, NCT02561026) and one has been completed
(Müller 2015). The completed study randomised a total of 81
adults in intensive care with coagulopathy (INR 1.5 or greater)
who were due to undergo an invasive procedure to receive ei-
ther prophylactic fresh frozen plasma (FFP) at 12 mL/kg or to
receive no FFP; of these participants, 58 underwent central ve-
nous catheterisation (the remainder underwent other invasive pro-
cedures such as chest drain insertion). It is the subgroup of 58
patients undergoing central venous catheter (CVC) insertion that
were included in this review.
In the Müller 2015 trial there were no reported episodes of major
bleeding within 24 hours of the procedure, there was therefore
insufficient evidence to determine a difference in this primary
outcome.
There was insufficient evidence to determine the risk of minor
procedure-related bleeding (risk ratio (RR) 0.67; 95% confidence
interval (CI) 0.12 to 3.70).No serious adverse eventswere reported
by this study.
The proportion of participants who died due to any cause, as well
as the change in INR in the 24 hours following the procedure,
were not made available for the subgroup of 58 patients in the
Müller 2015 trial who underwent central venous catheterisation.
Outcomes relating to the proportion of recipients receiving plasma
or red cell transfusions within 24 hours of the procedure; serious
adverse events (transfusion-related within 24 hours of the proce-
dure and line-related within seven days of the procedure); total
number of days in hospital and quality of life were not reported
by the included study.
Overall completeness and applicability of
evidence
The conclusions which can be drawn following this systematic
review are very limited due to the inclusion of only one RCT
(Müller 2015), from which only 58 patients were included in this
review. There was insufficient evidence to determine the effect of
plasma transfusion prior to central line insertion on the primary
outcomes of all-cause mortality or major procedure-related bleed-
ing. There were insufficient data to determine the effect on mi-
nor procedure-related bleeding or any other secondary outcome.
There are three ongoing RCTs (NCT02311985, NCT02561026,
NCT02637427), which are scheduled to complete recruitment
by February 2018.
These three ongoing studies (expected recruitment 355 partici-
pants in total) will be too small to provide sufficient data for this
review’s primary outcomes. For example, if we assumed that major
bleeding occurred in 1 out of 100 people who had a central line
when their INRwas 1.5 or less, and that the risk of major bleeding
doubled to 2 out of 100 people when their INR was only 5 or less,
we would need to design a study with at least 4634 participants
to detect this difference with 80% power and 5% significance
(6202participants required todetect a differencewith 90%power)
(calculated using a power calculator at www.sealedenvelope.com/
power/binary-superiority/).
Quality of the evidence
The Müller 2015 study was stopped early as it failed to recruit
sufficient participants, as such it was underpowered; investigators
were only able to randomise 20% of the targeted number of par-
ticipants, leading to a high risk of Type II error. There was low
risk of selection or attrition bias. Clinicians and participants were
unblinded to the intervention, leading to a high risk of perfor-
mance bias. Although the primary outcome was pre-specified and
reported, minor changes were made to secondary outcomes be-
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tween trial registration and reporting, increasing the risk of report-
ing bias. There was an imbalance in the number of participants
who had liver disease between the two study arms, increasing the
risk of other bias.
Overall, the quality of evidencewas rated according to theGRADE
methodology as very low across difference outcomes due to the
high risk of bias in the included study and the imprecision of the
estimates.
We assessed the GRADE quality of evidence as very low for:
• major procedure-related bleeding within 24 hours of the
procedure.
• minor procedure-related bleeding within 24 hours of the
procedure.
We could not assess the quality of the evidence for: all-cause mor-
tality; respiratory deterioration attributable to transfusion-associ-
ated circulatory overload (TACO), transfusion-related acute lung
injury (TRALI) or transfusion-associated dyspnoea (TAD); acute
transfusion reactions) within 24 hours of the procedure; propor-
tion of participants receiving plasma transfusions within 24 hours
of the procedure; line-related complications within seven days of
the procedure (infection, thrombosis, other); or quality of life be-
cause these outcomes were not reported.
Potential biases in the review process
We conducted a comprehensive search of multiple databases and
clinical trial registries to capture all relevant RCTs. We only in-
cluded one study reported in English, however no relevant non-
English language studies were identified in the search. There are
three ongoing studies. Two assessors carefully screened all papers
identified by the search and performed data extraction. We pre-
specified all outcomes prior to undertaking the search. We were
unable to undertake a meta-analysis or assess publication bias as
only one study was included in this review.
Agreements and disagreements with other
studies or reviews
We are not aware of any other systematic reviews of RCTs which
assess the effect of plasma transfusion prior to central line insertion
for people with abnormal coagulation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The conclusion of this systematic review is that currently there
exists only very limited evidence from one randomised controlled
trial (RCT) to inform the decision whether or not to administer
prophylactic plasma prior to central venous catheterisation for
people with abnormal coagulation. It is not possible from the
current RCT evidence to recommend whether or not prophylactic
plasma transfusion is beneficial or harmful in this situation.
Implications for research
It is common for people who are critically ill to become coagulo-
pathic, and many of these will require insertion of a central venous
catheter (CVC). The question of whether prophylactic plasma
transfusion is indicated remains unanswered. An adequately-pow-
ered trial which is able to recruit sufficient number of participants
to address this is required. The ongoing trials that are due to be
completed by February 2018 will be unable to answer the primary
questions of this review because the studies are too small. To de-
tect a doubling in the number of participants with major bleeding
from 1% to 2% would require a two-arm study with over 4600
participants; the three ongoing studies are only planning to recruit
355 participants in total.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Müller 2015
Methods National, multi-centre, randomised, open-label trial with blinded endpoint evaluation
Enrolled May 2010 to June 2013.
Participants Inclusion criteria: Adults in intensive-care (aged 18 years and older) with an INR greater
than or equal to 1.5 undergoing insertion of a central venous catheter, thoracocentesis,
percutaneous tracheotomy, or drainage of abscess or fluid collection (n = 81)
Exclusion criteria: People with clinically overt bleeding (defined as either a decrease in
haemoglobin [Hb] > 16 g/L or a need for transfusion or haemodynamic instability due
to bleeding at the time of the procedure); thrombocytopenia of less than 30 × 109/L;
patients treated with vitamin K antagonists, activated protein C, abciximab, tirofiban,
ticlopidine, or prothrombin complex concentrates; patients with a history of congenital
or acquired coagulation factor deficiency or bleeding diathesis; use of heparin < 1 hour
before the procedure; use of therapeutic doses of low molecular weight heparin < 12
hours before the procedure
Number screened: A total of 1478 patients had an INR of at least 1.5 and not more
than 3.0. Of these, 615 patients did not fulfil inclusion criteria, leaving 263 patients
with an INR of at least 1.5 and not more than 3.0 scheduled to undergo a pre-defined
intervention. Of these, 65 patients declined informed consent. An additional 83 patients
were missed and 34 patients did not participate due to other reasons, including refusal
from treating physicians to include a specific patient (3.8%)
Number recruited: 81 participants. Five did not undergo an intervention and were
therefore excluded from further analysis (2 FFP; 3 no FFP)
Age: FFP: median 64 years (IQR 54 to 70): no FFP: median 66 years (IQR 62 to 72)
Gender: Male 44 (FFP 26; no FFP 18); Female 32 (FFP 12; no FFP 20)
Platelet count: FFP: median 92 x 109/L (IQR 52 to 180), no FFP: median 110 x 109/
L (IQR 52 to 183)
Number analysed for primary outcome: 76 participants (38 FFP and 38 no FFP)
Interventions Participants assigned to receive or not to receive a single dose of 12 mL/kg FFP
Arm 1: assigned to FFP (n = 40); underwent a CVC insertion (n = 29)
Arm 2: assigned to no FFP (n = 41); underwent a CVC insertion (n = 29)
Outcomes Primary outcome: Procedure-related bleeding, occurring within 24 hours after the pro-
cedure
Secondary outcomes: Effects of FFP on correction of INR and additional transfusion
requirements; development of lung injury 24 hours after intervention; incidence of
ventilator-associated pneumonia (VAP)
Assessment of bleeding Major bleeding: defined as bleeding accompanied by a decrease in Hb by more than
20 g/L in the absence of another cause of bleeding; transfusion of 2 or more units
RBCs without an increase in Hb; a decrease in systolic blood pressure by more than
20 mmHg; an increase in heart rate by 20 beats per minute or more; wound-related
bleeding requiring an intervention
Minor bleeding: defined as prolonged bleeding at the site of insertion or increase in size
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Müller 2015 (Continued)
of subcutaneous haematoma
Notes Trial registration: NCT01143909 and NTR 2262 (registered 26 March 2010)
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Location of trial: Netherlands
Number of study centres: 4
Sample size calculation: was based on the assumption that the occurrence of major
bleeding in patients with a coagulopathy undergoing invasive procedures was less than
1%. Group size calculation was focused on demonstrating noninferiority.With a sample
size in each group of 198, a one-sided Z test with continuity correction (pooled) achieved
80% power to reject the null hypothesis that the proportion of bleeding patients in the
experimental group (no FFP transfusion) was higher, that is, inferior to the proportion
in the control group (FFP transfusion) with a margin of 0.03. It was assumed that the
expected difference in proportions is zero and the proportion in the control group is
0.01. The one-sided significance level of the test was targeted at 0.05. Therefore, the
authors intended to enrol 200 patients per treatment arm
Owing to slow inclusion, the trial was stopped before the pre-defined target enrolment
was reached
Conflict of interests: NPJ reported grants from the Netherlands Organisation for Sci-
entific Research (NWO), during the conduct of the study. The other authors disclosed
no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization procedure is pass-
word protected, web-based, using per-
muted blocks and stratified by study centre
and invasive procedure”
Allocation concealment (selection bias) Low risk “The randomization procedure is pass-
word protected, web-based, using per-
muted blocks and stratified by study centre
and invasive procedure”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Investigators and clinicians were unblinded
to the intervention. It is unclear how many
participants were sedated and not aware of
the intervention. “Since manufacturing a
completelymatchedplacebo in full compli-
ance with the current good manufacturing
practice standards was considered not pos-
sible, a prospective, randomized, open-la-
bel, blinded endpoint evaluation (PROBE)
design was chosen.”
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Müller 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The potential bleeding site was assessed by
a physician blinded to the interventionwho
filled out a predefined bleeding score form
consisting of blood pressure, heart rate, Hb
level, and occurrence of procedure-related
bleedingwith or without the need for inter-
vention or transfusion. Subsequently this
blinded physician assigned a score of major
bleeding, minor bleeding, or no bleeding
at 1 and 24 hours after the intervention.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants who were randomised and
underwent an invasive procedure were in-
cluded in the analysis
Selective reporting (reporting bias) Unclear risk The primary outcome was pre-specified
and reported (“procedure related relevant
bleeding, occurring within 24 hours after
the procedure”)
Minor changes were made to secondary
outcomes between trial registration and re-
porting. Acute lung injury was reported at
24 hours, rather than 48 hours as specified
in the trial registration. No evaluation of
costs was reported, despite this being regis-
tered as a secondary outcome
Other bias High risk The major limitation of this trial was that
it was stopped early due to slow inclusion.
Despite the addition of extra recruitment
sites, the study was only able to randomise
20% of the targeted participant number.
There was an imbalance in the number of
participants with a history of liver disease
between treatment arms. 45% (17/38) of
participants had liver disease in the no FFP
armwhereas only 16% (6/38) had liver dis-
ease in the FFP arm
CVC: central venous catheter; FFP: fresh frozen plasma; INR: International Normalised Ratio; IQR: interquartile range; RBC: red
blood cell
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alport 2012 Comparison of different peripherally- inserted central venous catheters in non-coagulopathic patients
Amarapurkar 2014 Non-randomised observational study
Bartelmaos 2013 Comparison of quarantine, methylene blue and solvent/detergent plasmas in liver transplant recipients
Carino 2009 Non-randomised observational study
Corash 2006 Comparison of standard FFP and photochemically-treated FFP in coagulopathic patients prior to invasive
procedures
De Pietri 2016 Comparison of FFP transfusion guided by thromboelastography versus standard coagulation tests prior to
invasive procedures. Fewer than 10% of included participants received central venous catheterisation
Etemadrezaie 2007 Comparison of FFP and saline in severe traumatic brain injury
Freeman 1998 Comparison of solvent/detergent FFP and standard FFP in orthotopic liver transplantation
Friedman 1989 Non-randomised, observational study
Gallieni 1995 Case-series
Harter 2004 Commentary
Holcomb 2015 Comparison of plasma:platelet: red blood cell ratios in severe trauma with massive haemorrhage
Mintz 2006 Comparison of photochemically-treated and standard FFP in patients with coagulopathy of liver disease
Napolitano 2012 Non-randomised, observational study
NCT00233246 Study withdrawn prior to enrolment
NCT00953901 Study withdrawn prior to enrolment
NCT01754545 Study withdrawn prior to enrolment; wrong subject group
Tinmouth 2008 Comparison of high and standard dose FFP in coagulopathic patients undergoing invasive procedures
Weigand 2009 Non-randomised, observational study
Williamson 1999 Comparison of solvent/detergent and standard FFP
FFP: fresh frozen plasma
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Characteristics of ongoing studies [ordered by study ID]
NCT02311985
Trial name or title Point-of-care versus standard coagulation tests versus restrictive strategy to guide transfusion in chronic liver
failure patients requiring central venous line: prospective randomised trial
Methods Single centre. Double-blind, randomised-controlled trial.
Participants Inclusion Criteria:
Adults (18 years or older) with chronic liver disease requiring central venous catheterisation
Exclusion Criteria:
• Acute liver failure
• Use of therapeutic doses of oral or parenteral anticoagulants (unfractionated heparin or low molecular
weight heparin or oral anticoagulants)
• Use of oral or parenteral platelet aggregation inhibitors
• Patients with von Willebrand syndrome
• Over-the-guidewire central venous catheter changing
• Patients previously included in this study protocol during the same hospital stay
Interventions Transfusion of fresh-frozen plasma, platelets and/or cryoprecipitate following the use of standard tests of coag-
ulation (INR > 1.5, APPT > 50s) versus thromboelastometry (ROTEM) versus standard tests of coagulation
with a restrictive threshold (INR > 5, platelets < 25 x 109/L)
Outcomes Primary outcome: proportion of participants receiving FFP, platelets and/or cryoprecipitate prior to central
venous catheterisation
Secondary outcomes: incidence of bleeding; adverse consequences of blood product transfusion; cost; dura-
tion of ICU stay; duration of hospital stay; 28-day mortality
Starting date September 2014
Estimated Study Completion Date: December 2016
Contact information Dr Leonardo Rocha - lrocha23@gmail.com
Notes Trial registration: NCT02311985 on 3 December 2014
Planned recruitment: 165 adults
Sponsor: Hospital Israelita Albert Einstein
Location of trial: Brazil
Number of study centres: 1
NCT02561026
Trial name or title Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT)
Methods Three-centre, randomised, parallel-assignment open-label trial
Participants Inclusion Criteria:
• Aged 18 years or older
• Admission or planned admission (e.g. patients in emergency department who are being seen by the
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NCT02561026 (Continued)
ICU team) to an intensive care unit
• An elevated INR between 1.5 and 2.5.
• Requiring an invasive procedure in the next 24 hours including central venous line, arterial line,
paracentesis, thoracocentesis bronchoscopy, endoscopy, and ultrasound guided biopsy (mass or organ) or
fluid drainage.
Exclusion Criteria:
• Active bleeding, defined as visible or suspected blood loss in last 48 hours, resulting in a fall in
haemoglobin greater than or equal to 20 g/L, requiring a red cell transfusion or an intervention to control
bleeding.
• Full dose therapeutic anticoagulation with warfarin, heparin, low molecular weight heparin, or other
novel oral anticoagulants.
• Congenital bleeding disorders including haemophilia, von Willebrand Disease or platelet function
disorders.
• Acquired coagulation factor deficiencies.
• Frozen plasma transfusion during this ICU admission.
• Use of other haemostatic blood products (recombinant factor VIIa, prothrombin complex concentrate,
cryoprecipitate, fibrinogen concentrate) during the ICU admission
• Previously enrolment in the study.
Patients will not be excluded for thrombocytopenia or antiplatelet drugs. As a pilot trial for a pragmatic
large randomised controlled trial, both thrombocytopenic patients and patients on antiplatelet agents will be
enrolled as they are routinely encountered in clinical practice
Interventions Transfusion of fresh-frozen plasma versus no transfusion prior to invasive procedure
Outcomes Primary outcome: recruitment feasibility
Secondary outcomes: bleeding assessment; ventilator requirement; overall hospital length of stay; ICU length
of stay
Starting date January 2016
Estimated Study Completion Date: February 2018
Contact information Elizabeth Chatelain - echatelain@ohri.ca
Notes Trial registration: NCT02561026 on 15 July 2015
Planned recruitment: 80 adults
Sponsor: Ottawa Hospital Research Institute
Location of trial: Canada
Number of study centres: 3
NCT02637427
Trial name or title Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures?
Methods Multi-centre, single-blind, parallel assignment randomised controlled trial
Participants Inclusion Criteria:
Adults (aged 21 years or older) with an INR between 1.5 and 2.5 undergoing an invasive procedure at the
bedside, in an endoscopy suite or in a radiology department
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Exclusion Criteria:
• Undergoing a surgical procedure in the operating room
• Active bleeding
• Undergoing a procedure involving or proximal to the central nervous system or spinal cord
• Cardiac catheterisation
• Using 4 factor plasma concentrates
• Using systemic heparin/heparinoid therapy, direct factor X inhibitors and other anticoagulants for
which plasma will not correct prolonged INR
• Platelet count less than 50 x 109/L
• Congenital coagulation disorders
• Acquired coagulation disorders (i.e., lupus anticoagulant) for which plasma will not correct the disorder
• Women who are pregnant
• Unwillingness to consider blood transfusion
Interventions Transfusion of fresh frozen plasma (10 mL to 20mL/kg to a maximum of 5 units) versus no transfusion prior
to an invasive procedure
Outcomes Primary outcomes: change in haemoglobin level; trial feasibility
Secondary outcomes: rate of red cell transfusion; transfusion-associated circulatory overload; transfusion-
associated acute lung injury;major bleeding; change in INRpost-procedure, at day one and day two;mortality;
infection; ICU admission
Starting date January 2016
Estimated Study Completion Date: May 2017
Contact information Dr Paul Ness - pness@jhmi.edu
Notes Trial registration: NCT02637427 on 16 December 2015
Planned recruitment: 110 adults
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Location of trial: United States
Number of study centres: 4
APTT: activated partial thromboplastin time; ICU: intensive care unit; INR: International Normalised Ratio
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D A T A A N D A N A L Y S E S
Comparison 1. Plasma transfusion versus no plasma transfusion
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Minor bleeding 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
C O N T R I B U T I O N S O F A U T H O R S
David Hall: protocol and review development, searching, selection of studies, eligibility and quality assessment, data extraction and
analysis and content expert.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Aspects of the protocol that were not implemented due to lack of data
There were several differences between the protocol (Hall 2015) and this review due to lack of data.
Interventions
We could not perform five of the six planned comparisons, because the one included study did not compare these interventions.
No studies were identified that compared: no plasma transfusion prior to central line insertion versus plasma transfusion when the INR
is greater than 3 times control; OR plasma transfusion when rotational thromboelastography is above a certain threshold (as defined
by the study).
No studies were identified that compared: plasma transfusion prior to central line insertion when the INR is greater than 1.5 times
control; versus plasma transfusion prior to central line insertion when the INR is 2 to 3 times control; OR plasma transfusion when the
INR is greater than 3 times control;plasma transfusion when rotational thromboelastography is above a certain threshold (as defined
by the study).
Primary outcomes
The included study did not report the following review outcomes.
• All-cause mortality up to 30 days after the procedure.
Secondary outcomes
The included study did not report the following review outcomes.
• Serious adverse events:
• ◦ transfusion-related complications within 24 hours of the procedure (including transfusion-related acute lung injury
(TRALI), transfusion-transmitted infection, transfusion-associated circulatory overload (TACO), transfusion-associated dyspnoea
(TAD), acute transfusion reactions);
◦ line-related complications within seven days of the procedure (infection, thrombosis, other).
• Total number of days in hospital.
• Proportion of participants receiving plasma transfusions and red cell transfusions within 24 hours of the procedure.
• Change in INR up to 24 hours following the procedure.
• Quality of life, as defined by the individual studies.
Measures of treatment effect
The included study did not report any continuous outcomes or hazard ratios.
We did not report the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for
an additional harmful outcome (NNTH) with confidence interval (CIs), because the only analysis performed did not demonstrate a
benefit or harm.
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Data extraction and management
We could not pilot the data extraction form on two included RCTs because there was only one included RCT.
Assessment of heterogeneity
We did not perform an assessment of heterogeneity as the review included only one completed study.
Assessment of reporting biases
We did not perform a formal assessment of potential publication bias (Lau 2006; Sterne 2011) as the review included only one trial.
Data synthesis
Meta-analysis was not feasible as the review included only one completed study.
Subgroup analyses
Inadequate data were available to perform subgroup analyses. We had planned to carry out these for each of the following outcomes in
order to assess the effect on heterogeneity.
• Type of central line inserted (venous tunnelled, venous untunnelled, porta-cath, whether an emergency or elective procedure).
• Type of participants (intensive care, liver disease, other).
• Age of participants (neonate, child (one to 15 years), adult (16 years or older)).
• Whether participants had associated platelet count abnormalities.
Sensitivity analyses
Only one completed study was identified in this review and therefore no sensitivity analyses could be performed.
N O T E S
This review is a rapid review (definition of a rapid review as previously agreed with the Cochrane Haematological Malignancies Group),
and includes only English language publications.
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